Ascendis Pharma A (ASND) Other Accumulated Expenses (2017 - 2026)

Ascendis Pharma A has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $454.4 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $454.4 million, up 65.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $454.4 million (up 65.27% YoY), and the FY2025 annual result was $446.7 million, up 39.82% from the prior year.
• Other Accumulated Expenses came in at $454.4 million for Q1 2026 at Ascendis Pharma A, up from $446.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $454.4 million in Q1 2026 to a low of $192.0 million in Q1 2024.
• The 4-year median for Other Accumulated Expenses is $297.9 million (2024), against an average of $319.2 million.
• Across the five-year window, Other Accumulated Expenses surged 35.38% in 2025 and soared 65.27% in 2026, its largest moves.
• Ascendis Pharma A's Other Accumulated Expenses stood at $200.3 million in 2023, then soared by 59.55% to $319.5 million in 2024, then surged by 39.82% to $446.7 million in 2025, then gained by 1.71% to $454.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $454.4 million (Q1 2026), $446.7 million (Q4 2025), and $381.7 million (Q3 2025), per Business Quant data.